Dexcom Sets Sight On Artificial Pancreas With Acquisition Of Typezero Technologies Company

[DCUK NewsBot]

Dexcom has its sights set on being a leader in artificial pancreas technology after acquiring TypeZero Technologies, a company that has a system designed to manage and regulate insulin delivery from insulin pumps. With the acquisition, Dexcom puts itself in a position to be a major player in the development of artificial pancreas technology. The companies are confident that they'll have an automated insulin delivery system within 2019. It is exciting, for people with type 1 diabetes in particular, that artificial pancreas technology is becoming a major focus of some of the largest diabetes technology companies. TypeZero Technologies is a company that came out of the University of Virginia. The company has developed a mobile app and insulin regulation system called inControl. The system is able to stop insulin delivery when low blood sugar levels are predicted to occur and to deliver bolus doses if blood sugar levels go too high. TypeZero provides a diabetes management platform for people with diabetes and a platform for use by healthcare professionals. TypeZero has been working with a number of insulin pump companies, including Tandem Diabetes Care and Cellnovo. TypeZero has been working with Tandem Diabetes Care since 2016. An automated insulin delivery system looks set to include Dexcom's CGM technology, Tandem's t:slim X2 insulin pump and TypeZero's inControl diabetes management system. The plan is to allow TypeZero's inControl system to be compatible with a number of different insulin pumps and continuous glucose monitors (CGMs). This would mean that the system would be plug and play and would be accessible to a wide range of people, not just those with a specific pump and CGM combination. There are already a number of diabetes firms and universities working on artificial pancreas technology. Having a large, forward-thinking firm like Dexcom will widen the possibilities for people with diabetes and continue to push technology development further as firms compete to improve.

Continue reading...

 

[kitedoc]

Thank you. It helps to confirm my choice for the long term of the Tandem Slim when my Animas pump is out of warranty next year.

 

[BeccyB]

"they'll have an automated insulin delivery system within 2019."

does that mean they'll have one ready to begin testing, or one ready for market??! There's a world of difference.

Definitely good to see Dexcom throwing their weight behind something though

 

[tim2000s]

Feedback on Basal:IQ on the Tandem devices (the equivalent of the Medtronic Smartguard algorithm on the 640G) has been very good from users in the US. Control:IQ, which is the equivalent of the 670G, is due out later this year in the US, so you should see a much more competitive "artificial Pancreas" market over the next year or so.